LINC01667

Across TCGA pan-cancer cohorts, LINC01667 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC01667’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC01667 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01667 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

LIHC, UCEC, and BRCA are the cancer types where LINC01667 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01667 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.465	.001	4	view →
UCEC	All	IV	+2.180	.020	2	view →
BRCA	All	III,IV	−0.220	<.001	2	view →
LUSC	All	All	+0.206	.031	1	view →
LUSC	Male	II,III,IV	−0.025	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 4 lineages.

LINC01667–LIHC

Open the LIHC breakdown →